The amount raised in Hong Kong under the revamped rules paints a favourable picture, with nine biotech IPOs in the year to April 17 raising a combined US$3.8 billion. Photo: Bloomberg

A year after Hong Kong’s stock listing overhaul, city’s aim to be Asia’s biotech hub is still a work in progress

  • Less than 10 firms have taken advantage of the radical listing reforms, but their IPO proceeds are the second biggest worldwide
  • Challenges ahead as Shanghai’s new tech board attracts large number of applicants
Topic |   IPO

TOP PICKS

The amount raised in Hong Kong under the revamped rules paints a favourable picture, with nine biotech IPOs in the year to April 17 raising a combined US$3.8 billion. Photo: Bloomberg
READ FULL ARTICLE